Business Context and Reporting Period
Company: Arcturus Therapeutics Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2026
Event: Entry into a Material Definitive Agreement with Thermo Fisher Scientific Inc. and affiliates.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a strategic collaboration agreement with the following financial terms:
- Clinical Manufacturing Services: Thermo Fisher to contribute up to $40 million for ARCT-032.
- CRO Services: Arcturus to engage PPD, Inc. (Thermo Fisher affiliate) for up to $40 million.
- Commercial Rights: Upon regulatory approval of ARCT-032, Thermo Fisher receives exclusive commercial manufacturing rights for a specified duration (terms to be negotiated).
Material Changes
The primary material change is the establishment of a strategic collaboration for the development of ARCT-032, an investigational mRNA therapeutic for cystic fibrosis. This agreement secures long-term CDMO and CRO support through a Master Services Agreement (MSA) and a Project Addendum.
Guidance, Outlook, and Risks
Management Commentary: The collaboration is structured to support the development of ARCT-032 through technical transfer, engineering batches, clinical trial material manufacture, and stability studies.
Outlook: The MSA has an initial term of five years with automatic one-year renewals unless terminated with 90 days' notice.
Contingencies: Exclusive commercial manufacturing rights for Thermo Fisher are contingent upon regulatory approval of ARCT-032. Arcturus may engage an alternative manufacturer only if Thermo Fisher is unable to supply necessary quantities.
Investor Verification Checklist
- Verify the full text of the Master Services Agreement and Project Addendum when filed as exhibits to the Form 10-Q for the quarter ending June 30, 2026.
- Confirm the specific duration and terms of the exclusive commercial manufacturing rights to be negotiated upon regulatory approval.
- Monitor the progress of ARCT-032 clinical trials to assess the utilization of the $40 million service commitments.
- Review the July 2, 2026 press release (Exhibit 99.1) for additional details on the strategic partnership.